Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

OTO-313 in Subjects With Unilateral Subjective Tinnitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04829214
Recruitment Status : Active, not recruiting
First Posted : April 2, 2021
Last Update Posted : February 23, 2022
Sponsor:
Information provided by (Responsible Party):
Otonomy, Inc.

Brief Summary:
The purpose of this study is to determine the efficacy of OTO-313 in subjects with unilateral tinnitus and to determine the safety and tolerability of OTO-313 in subjects with unilateral tinnitus.

Condition or disease Intervention/treatment Phase
Subjective Tinnitus Drug: OTO-313 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 153 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, double-blind, placebo-controlled, multicenter
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Phase 2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Unilateral Subjective Tinnitus
Actual Study Start Date : March 22, 2021
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : August 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tinnitus

Arm Intervention/treatment
Experimental: OTO-313 Drug: OTO-313
Single intratympanic injection

Placebo Comparator: Placebo Drug: Placebo
Single intratympanic injection




Primary Outcome Measures :
  1. Change from Baseline in Tinnitus Functional Index (TFI) [ Time Frame: Week 4, Week 8 ]
    The TFI is a validated, 25-item questionnaire; index score from 0 to 100; higher scores indicate a greater problem with tinnitus


Secondary Outcome Measures :
  1. Daily Tinnitus Loudness [ Time Frame: Start of Lead-in (2 weeks before Baseline) to end of study (Week 16) ]
    Numerical rating scale from 0 (No Tinnitus) to 10 (Extremely Loud Tinnitus) collected every day

  2. Daily Tinnitus Annoyance [ Time Frame: Start of Lead-in (2 weeks before Baseline) to end of study (Week 16) ]
    Numerical rating scale from 0 (Not Annoying) to 10 (Extremely Annoying) collected every day

  3. Patient Global Impression of Change [ Time Frame: Week 4, Week 8, Week 12, Week 16 ]
    Change in overall tinnitus status as perceived by the subject


Other Outcome Measures:
  1. Treatment Emergent Adverse Events [ Time Frame: Reported or observed during or after dosing (Baseline) up to end of study (16 Weeks) ]
    An adverse event (AE) is any unfavorable and unintended diagnosis, symptom, sign, syndrome or disease which occurs during the study, having been absent at baseline, or, if present at baseline, appears to worsen. Treatment emergent means it started during or after dosing.

  2. Audiometry [ Time Frame: Screening, after dosing (Baseline) up to end of study (16 Weeks) ]
    Hearing function - clinically significant adverse change from Baseline

  3. Otoscopic Examinations [ Time Frame: After dosing (Baseline) up to end of study (16 Weeks) ]
    Ear examination - clinically significant adverse change from Baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has early-onset subjective unilateral tinnitus that is persistent (consistently aware of their tinnitus throughout much of the waking day).
  • Subject is able to use the diary to complete their daily tinnitus ratings.
  • Subject's tinnitus is likely of cochlear origin, e.g., associated with sensorineural hearing loss; acute hearing loss from noise trauma, barotrauma, or traumatic cochlear injury (acute acoustic trauma, blast trauma, middle ear surgery, inner ear barotrauma); age related hearing loss; resolved otitis media; ototoxic drug exposure.
  • Subject is willing to comply with the protocol and attend all study visits.

Exclusion Criteria:

  • Subject has pulsatile tinnitus, temporomandibular joint disease (TMJ) associated with tinnitus perception, tinnitus resulting from traumatic head or neck injury, or tinnitus resulting from a tumor or stroke.
  • Subject is pregnant, lactating, or undergoing fertility treatment.
  • Subject has other clinically significant illness, medical condition or medical history at Screening or Baseline that, in the Investigator's opinion, would likely reduce the safety of study participation or compliance with study procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04829214


Locations
Show Show 48 study locations
Sponsors and Collaborators
Otonomy, Inc.
Layout table for additonal information
Responsible Party: Otonomy, Inc.
ClinicalTrials.gov Identifier: NCT04829214    
Other Study ID Numbers: OTO-313-201
First Posted: April 2, 2021    Key Record Dates
Last Update Posted: February 23, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Otonomy, Inc.:
intratympanic injection
IT injection
gacyclidine
tinnitus
Additional relevant MeSH terms:
Layout table for MeSH terms
Tinnitus
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases